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Abstract Epigenetic regulations of genes by reversible
methylation of DNA (at the carbon-5 of cytosine) and
numerous reversible modifications of histones play important
roles in normal physiology and development, and epigenetic
deregulationsareassociatedwithdevelopmentaldisordersand
various disease states, including cancer. Stem cells have the
capacity to self-renew indefinitely. Similar to stem cells, some
malignantcellshavethecapacitytodivideindefinitelyandare
referred to as cancer stem cells. In recent times, direct
correlation between epigenetic modifications and reprogram-
ming of stem cell and cancer stem cell is emerging. Major
discoveries were made with investigations on reprogramming
gene products, also known as master regulators of totipotency
and inducer of pluoripotency, namely, OCT4, NANOG,
cMYC, SOX2, Klf4, and LIN28. The challenge to induce
pluripotency is the insertion of four reprogramming genes
(Oct4, Sox2, Klf4, and c-Myc) into the genome. There are
always risks of silencing of these genes by epigenetic modi-
fications in the host cells, particularly, when introduced
through retroviral techniques. In this contribution, we will
discuss some of the major discoveries on epigenetic mod-
ifications within the chromatin of various genes associated
with cancer progression and cancer stem cells in comparison
to normal development of stem cell. These modifications may
be considered as molecular signatures for predicting disorders
of development and for identifying disease states.
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Introduction
Defining the growth requirements for the maintenance
and differentiation of developmental and cancer cells,
and attempts to define their predictive molecular signa-
tures have proved frustrating in the past. However,
currently there has been remarkable progress in under-
standing molecular mechanisms of development and
cancer biology. Under certain conditions of cell cycle
control mechanisms, cells of many developing organs
and cancer cells of those particular organs follow general
mechanisms and may be compared for understanding the
disease state. Some studies examining specific epigenetic
features of embryonic and cancer stem cells—such as the
aberrant DNA-methylation, abundance of modified his-
tones, Polycomb group (PcG) protein binding patterns,
replication timing, and chromatin accessibility have
provided important insights into the unique properties
of stem cells. Here, we discuss the unique epigenetic
features of developmental and cancers stem cells, and
explore the new questions that these findings have raised
about stem cells, cancer stem cells, and their implications
for practical applications.
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Indefinite self-renewal and multipotency are two funda-
mental properties of Stem cells. They have the capacity to
divide with at least one daughter retaining the phenotype of
the mother (Pardal et al. 2003a; Gupta and Massagué 2006;
Rapp et al. 2008; Michor 2008; Hart and El-Deiry 2008;
Maitland and Collins 2008). Conceptually there are two
major types of stem cells: namely, embryonic stem (ES)
cells and adult stem cells. Embryonic development is a
process of differentiation, growth, and maturation of
different organs by which all the tissues and cells of an
organism are derived from zygotic stem cells. This property
is defined by the ways of conversion of totipotency to
pluripotency to multipotency to unipotency (See Scheme 1).
In adult organisms, cells of many tissues retain their
stemness properties and play critical roles in tissue
regeneration and repair. These adult stem cells are consi-
dered pluripotent as generally they have limited ability for
differentiation and are committed to create the mature
differentiated cells in the tissues where they reside. This
differentiation process is part of the homeostatic system that
can renew senescent differentiated cells and replace tissue
loss following injury. In many tissues, it is now proven that
homeostasis is maintained by a hierarchical system in
which, firstly, stem cells generate transit-amplifying cells.
These rapidly cycling cells maintain a degree of multi-
potency and can expand and differentiate into non-cycling,
terminally differentiated cells. This hierarchy is prominent
in most of the cells of epithelial origin, including gut,
breast, lung, prostate, skin, cornea, and liver (Leedham et
al. 2005; Kakarala and Wicha 2008; Otto 2002; Richardson
et al. 2004a; Tsujimura et al. 2002; Alonso and Fuchs 2003;
Lavker et al. 2004; Vessey and de la Hall 2001).
Embryonic stem cells are derived from embryos and the
derivation of human embryonic stem cell (hESC) line has
involved embryo destruction. Many people have ethical
objections to their use for any purpose other than repro-
duction. But at present, derivation of at least five hESC
lines is possible without embryo destruction. hESC may be
cultured in three different ways. In first two processes
blastomere cocultured with green fluorescent protein
(GFP)-labeled hESC for 12–24 and 12 h, respectively, in a
modified medium (blastocyst medium supplemented with
laminin and fibronectin) which is approximately similar to
the inner cell mass (ICM) niche. In another process,
blastomeres were cultured in blastocyst medium without
GFP-hESC.Inthesethreeprocesses,stablehESC generated
3.8%, 20% and 50%, respectively, and cultures were stable
hESC to re-differentiate in vivo and vitro. Blastomere
culture medium was supplemented with laminin and
fibronectine. Laminin is a component of basement mem-
branes and associated with induction of apical/basal
polarity, possibly which suppressed trophectoderm differ-
Totipotency = Germ cells and placenta, all somatic cell types                                            
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    Epidermal stem cell 
Germ line stem cell 
Scheme 1 Levels of stem-cell
state
28 Clin Epigenet (2011) 2:27–53ention (Chung et al. 2008). Stable induced pluripotent stem
cell was also generated from human fibroblasts by directly
delivering four reprogramming proteins (octamer binding
transcription factor, Oct4; Sox2; Klf4; and c-Myc) fused
with cell membrane penetrating peptide. These four
proteins induced pluripotent stem cells morphology,
proliferation, and expression profiles of characteristic
pluripotency markers were similar to human embryonic
stem cell (Kim et al. 2009). Adult stem cells derived from
skin cells or bone marrow cells upon treatment with
reprogramming proteins also have acquired the properties
of embryonic stem cells. But this work is not widely
accepted because of higher time required for the protein-
mediated process (poor efficiency) in comparison to the
gene delivery-mediated process. However, scientists believe
that by exploiting the potential of embryonic stem cells to
develop into any cells of the body, they may be able to treat
many incurable conditions, but there is lack of full under-
standing of the mechanisms of epigenetic silencing or
activation of genes.
Epigenetics related to development and cancer biology
Epigenetics is the study of the stable inheritance of phenotype
without altering the genotype manifested by changes in gene
expression (Probst et al. 2009). Epigenetic changes in
eukaryotic biology are best observed during cellular differ-
entiation (Probst et al. 2009; Klose and Bird 2006;J a e n i s c h
and Bird 2003; Feinberg et al. 2006; Jones and Baylin 2007).
During embryogenesis, totipotent stem cells become the
various pluripotent cell lines of the embryo which in turn
become fully differentiated cells. In other words, a single
fertilized egg cell—the zygote—changes into the many cell
types found in vertebrates. This process is regulated by
activating some genes while silencing many others by
complex processes of epigenetic regulations. It involves a
unique modification of DNA at the cytosine 5-carbon
position (hereafter, DNA-methylation), and numerous mo-
difications in histones for the activation or repression of
certain genes (Jones and Baylin 2007). Additionally, various
proteins associated with the chromatin folding and dynamics
may be activated or silenced. What this means is that every
cell in our body has the same programming/instruction
manual, but different cell types are using different chapters.
Most epigenetic changes that are involved with the chroma-
tin modifications related to gene expression only occur
within the course of one individual organism's lifetime, but
some epigenetic changes are inherited from one generation
to the next. Epigenetic processes include paramutation (the
result of heritable changes in gene expression that occur
upon interaction between alleles), gene bookmarking (a
mechanism of epigenetic memory that functions to transmit
through mitosis the pattern of active genes and/or genes that
can be activated to daughter cells), imprinting, gene
silencing, X chromosome inactivation, position effect,
reprogramming, transvection (an epigenetic phenomenon
that results from an interaction between an allele on one
chromosome and the corresponding allele on the homolo-
gous chromosome), maternal effects, the progress of
carcinogenesis, and many effects of teratogens, regulation
of histone modifications and heterochromatin formation, and
technical limitations affecting parthenogenesis and cloning
(Probst et al. 2009; Klose and Bird 2006; Jaenisch and Bird
2003; Feinberg et al. 2006; Jones and Baylin 2007;C h r i s t m a n
2002; Patra et al. 2008; Vaissiere et al. 2008; Patra and Szyf
2008;P a t r a2008a).
Epigenetic regulation of genes by DNA methylation
and histone modifications
Methylation at the carbon-5 position of cytosine base is the
only known stable modification of DNA, which occurs
primarily in CpG dinucleotides and is often altered in cancer
cells (Jones and Baylin 2007). This modification consists of
the covalent addition of a methyl group catalyzed by a
family of enzymes called DNA methyltransferases
(DNMTs), using S-adenosylmethionine as the donor of the
methyl group (Klose and Bird 2006;C h r i s t m a n2002; Patra
et al. 2008; Vaissiere et al. 2008; Patra and Szyf 2008; Patra
2008a). In mammals, the de novo methylation generally
does not occur during normal postgastrulation development
but is seen frequently during the establishment of cell lines
in vitro and in tumor tissues (Jones et al. 1990; Kawai et al.
1994). It was suggested that the maintenance of DNA
methylation depends on DNMT1 that specifically recognizes
hemi-methylated DNA and methylates the complementary
strand and de novo methylation is carried out by DNMT3a
and DNMT3b proteins (Klose and Bird 2006; Jaenisch and
Bird 2003). DNMT3a is involved in the nucleolar inactiva-
tion of resting and growth-arrested cells. Methylation of
DNA repeats in the region of centromeric satellite DNA is
specially maintained through Dnmt3b (Thompson et al.
2010). Recent data suggest that the DNMT1 protein is
methylated by the histone methyltransferase (e.g., SET7) and
demethylated by histone demethylase (e.g., LSD1) (Esteve et
al. 2009;W a n ge ta l .2009a), which increase or decrease
respectively the DNMT1 activity in the different stage of cell
cycle. DNA methylation can inactivate a gene in a number
of ways; for example by attracting CpG-methylated-DNA
binding proteins, by attracting histone deacetylases
(HDACs) and by inducing variations in histone methylation
(Jones and Baylin 2007; Patra et al. 2008; Patra and Szyf
2008; Patra 2008a). Only a small fraction of the eukaryotic
genome is transcriptionally competent. The state of chroma-
tin in these regions must be dynamic to meet the changing
transcriptional requirements of a cell. This balance between
Clin Epigenet (2011) 2:27–53 29euchromatin and heterochromatin ensures that the gene-
expression pattern of a given cell type is stably maintained in
daughter cells as a heritable state. In terms of CpG-
density, there are two types of gene promoters. One type
accounts for ∼50% of the genes in the mammalian
genome and contains unmethylated CpG-islands. The
o t h e rp r o m o t e rt y p ei sC p G - p o o ri nc o m p o s i t i o n ,a si s
the rest of the genome. Among the genes that have CpG-
poor promoters, it is not known for how many of those
CpG-methylation might have a modulatory role in their
transcription? High-CpG-density promoters (HCPs) are
associated with two classes of genes: ubiquitous “house-
keeping” genes and highly regulated “key developmen-
tal” genes (Saxonov et al. 2006). In ES cells, HCPs at
housekeeping genes are enriched with the transcription
initiation mark H3K4me3 (“univalent”)a n dg e n e sa r e
generally highly expressed, whereas HCPs at develop-
mental genes are enriched with both H3K4me3 and the
repressive mark H3K27me3 (“bivalent”)a n dg e n e sa r e
generally silent (Meissner et al. 2008; Mikkelsen et al.
2007; Bernstein et al. 2006).
Genome-wide decrease of DNA methylation certainly
contributes to development of cancers (Bedford and van
Helden 1987). This hypomethylation has been associated
with the emergence of chromosome instability both in
m o u s e( D o d g ee ta l .2005), and human neoplasms (Schulz
et al. 2002). However, it is the regional hypermethylation
of critical genes that has attracted immense interest in
understanding the pathogenesis of cancer (Patra et al.
2002). Methylated genes commonly found in cancer affect
diverse cellular processes, some of which have roles in
tumor physiology and signaling such as the hormonal
response (androgen receptor, AR; estrogen receptor 1/2;
retinoic acid receptor beta; retinoic acid receptor responder
protein 1), tumor invasion/architecture (adenomatous
polyposis coli, APC; caveolin 1; cluster of differentiation
44; E-cadherin 1; E-cadherin 13; laminin subunit alpha-3;
laminin subunit beta-3; laminin subunit gamma-2; uroki-
nase type plasminogen activator), cell cycle control (G1/S-
specific cyclin-D2; Cyclin-dependent kinase inhibitor 2
A), repair of DNA damage (glutathione-S-transferase P;
O-6 methylguanine DNA methyltransferase), and signal
transduction (disabled homolog 2-interacting protein;
death-associated protein kinase 1; endothelin receptor type
B; Ras Association domain Family 1A; Patra and Szyf
2008;P a t r a2008a; Patra et al. 2002;L ie ta l .2005; Joshua
et al. 2008). Some other genes are also demethylated, e.g.,
uPA (Pulukuri et al. 2007; Patra and Bettuzzi 2007),
heparanase (Ogishima et al. 2005), and clusterin (Rauhala et
al. 2008) which may have functional importance, especially
for the invasive phenotype. These epigenetic signatures and
changes have been reviewed extensively (Schulz and Hatina
2006;D o b o s ye ta l .2007; Cooper and Foster 2009).
Eukaryotic genomes undergo hundreds of modifications
in their core histones tails. One of the best-studied histone
modifications is acetylation, and histone acetylation events
play crucial roles in all kinds of nuclear phenomena
involving DNA, namely: replication, recombination, repair,
condensation, and transcription. Acetylation is catalyzed by
histone acetyltransferases (HATs) such as monocytic leu-
kemia zinc finger protein (MOZ), MOZ-related factor,
males-absent on the first protein, HIV-1 tat-interacting
protein (TIP60), and human acetylase binding to origin of
replication complex—ORC1 (Esteller 2007; Clayton et al.
2006; Kouzarides 2007), where acetyl-coenzyme A is the
donor of acetyl-group. Primary site of acetylation is the side
chain of lysine (K) residues of the all histones, but
frequencies are moderate for H4 and highest for H3.
Downstream molecular consequences of histone acetylation
are (a) binding of chromodomain proteins at sites where
lysines are acetylated and (b) alteration of histone–DNA
binding. The later event opens faces of DNA for further
interactions with macromolecules/enzymes for the events
like replication, repair, or transcription. The amount of
residual acetylation level depends on the precise balance
between the action of HATs and histone deacetylases
(HDACs). Until now, four classes of HDACs have been
identified: Class I are ubiquitously expressed in human cell
lines and tissues. Class II has tissue specific expression and
can shuttle between the nucleus and cytosol. The class III
family is numbers of NAD+dependent proteins (Liu et al.
2010; Ropero and Esteller 2007); and the class IV is
homologous to the class I and II cytoplasm, and it may be
responsible for the acetylation of non-histone proteins
(Ropero and Esteller 2007). HDAC1 and HDAC2 have
been shown to directly interact with DNMT1 (Robertson et
al. 2000; Rountree et al. 2000). We and others have shown
that HDACs are associated with cancer development (Liu et
al. 2010; Patra et al. 2001). Recently, it is observed that
inhibition of HDAC by chidamide in colon cancer cells
increase acetylation level in histone H3, and arrests the
cancer cell cycle at G1 phase by inhibiting the PI3K/Akt
and MAPK/Ras signaling pathways and promotes the
apoptosis of cancer cell (Liu et al. 2010). The addition of
an acetyl group to the lysine residue neutralizes the charge,
which relaxes the bound DNA from the histone complex.
As a consequence, portions of DNA with largely acetylated
histones result in euchromatin formation and activation of
gene transcription, while histone deacetylation is associated
with chromatin condensation (heterochromatinization) and
gene suppression. A survey of results published over the
last decades described that histone acetylation can modulate
gene transcription at global (genome-wide) and gene-
specific levels (Jones and Baylin 2007; Patra et al. 2008;
Vaissiere et al. 2008; Patra and Szyf 2008; Clayton et al.
2006; Kouzarides 2007; Liu et al. 2010; Ropero and
30 Clin Epigenet (2011) 2:27–53Esteller 2007; Robertson et al. 2000; Rountree et al. 2000;
Patra et al. 2001; Bedford and Clarke 2009; Li and Zhao
2008; Schulz and Hoffmann 2009a; Seligson et al. 2005;
Brown et al. 2000). It is now clearer that promoter-specific
hyperacetylation occurs in at the backyard of global
acetylation, preventing deacetylation on those sites that
activates basal transcription. This facilitates a rapid return
to the default state of acetylation when transcription is
turned on (Vaissiere et al. 2008; Patra and Szyf 2008;
Clayton et al. 2006; Kouzarides 2007; Brown et al. 2000)
Another major modification of histone tails is the methyl-
ation at several lysine (K) and arginine (R) residues. Histone
methylations are linked to both transcriptional activation and
repression.MethylatedKresidues,obtainedinH3atpositions
−4, −9, −27, −36, and −79, and in H4 at K 20. Lysine can be
mono-, di-, and trimethylated, whereas arginine (R) can
additionally be tetramethylated. The dimethylated form of R
may again be symmetric or asymmetric (Bedford and Clarke
2009). Histone methylation is reversible and catalyzed by
two families of enzymes called histone lysine methyltrans-
ferases and protein arginine methyltransferases, and the
methyl group can be removed by histone demethylases
(Kouzarides 2007; Bedford and Clarke 2009). Stunning
numbers of reversible modifications along with different
combinations of modification involving physical interactions
of enzymes and regulatory proteins in both directions throws
insights of complexity of epigenetic regulation by histone
modification (Patra and Szyf 2008;K o u z a r i d e s2007). In
reality, the consequences of histone methylation depend on
the modified residue, as we know that methylation of H3K4,
H3K36, or H3K79 correlates with the active gene transcrip-
tion; however, methylation at H3K9, H3K27, or H4K20 is
usually linked to gene repression. Moreover, mono-, di-, and
trimethylation at the same K residues lead to different levels
of gene activation or repression and are involved in distinct
cellular pathways (Patra and Szyf 2008; Li and Zhao 2008).
H3K27me3 represses the gene when located at promoter
region. It is specifically coupled with HOX gene repression
and X chromosome inactivation (Schulz and Hoffmann
2009a). Histone modifications are altered in cancer, and
since these are mitotically heritable, they can play the same
roles and undergo the same selective processes as genetic
alterations in the development of a cancer. It is essential to
identify the usual patterns of normal tissues before deter-
mining the altered patterns of histone modification in cancer.
To date, some examples from recent studies are available: for
example, lower level of H4K12-Ac is an indicator of
recurrence in prostate cancer (Seligson et al. 2005)a n d
increased H3K4 dimethylation and H3K18 acetylation
activation mark correlated with poor prostate cancer prog-
nosis (Schulz and Hoffmann 2009a). Moreover, specific
epigenetic gene silencing can also occur by aberrant
targeting of HDACs to the gene promoter, which causes
histone hypoacetylation (Seligson et al. 2005). Typical genes
silenced in this manner in various human cancers include the
tumor-suppressor gene p21WAF1 (cyclin-dependent kinase
inhibitor 1; Patra et al. 2001). Among the members of
polycomb repressive complex (PRC), the most studied is the
polycomb protein enhancer of zeste homologue 2 (EZH2),
an essential component of a protein complex that catalyzes
methylation of histone H3 at K9 contributing to transcrip-
tional repression of a large number of specific genes. PRC1
complex was also required for trimethylation at H3K27,
which is responsible for stable maintenance of gene
repression (Schulz and Hoffmann 2009a). EZH2 is overex-
pressed in high percentage in prostate cancer patients, with
moderate increases in localized tumors, and higher expres-
sion in metastatic cases. EZH2 overexpression may lead to
the stable downregulation of approximately 100 genes and
increased expression of a smaller number (Varambally et al.
2002). Moreover, global patterns of histone modification are
shown to be linked to the risk of prostate cancer recurrence
(Cooper and Foster 2009). Specifically, the activating histone
modifications H3K18 acetylation and H4 R3 dimethylation
have been reported to occur in many cases of prostate cancer
and to be associated with higher grades and a worse
prognosis (Seligson et al. 2005). New evidences are
accumulating against the convention: histone modifications
that mark inactive chromatin are associated with DNA-
hypermethylated promoters, whereas histone marks for
active chromatin are normally associated with hypomethy-
lated promoters. Using a ChIP-based microarray approach, it
was found that in prostate cancer and PC3 cell line around
5% of promoters (16% with CpG islands and 84% without
CpG islands) were enriched with H3K27me3, a modification
that marks inactive chromatin. The genes containing this
mark were specifically silenced in PC3 compared with
normal prostate epithelial cells even though most of the
promoter of the genes with CpG islands showed low levels
of DNA methylation (Kondo et al. 2008). Apart from
changes of chromatin state and dynamicity by methylation
and acetylation of histones, emerging evidence suggest a role
for phosphorylation, beyond chromatin condensation (Patra
and Szyf 2008;K o u z a r i d e s2007).
Molecular marks for identifying stem-cells
Each cell in our body has its unique epigenetic mark. These
epigenetic marks establish their genotype, developmental
history and it reflects into the phenotype of the cell
(Table 1). During the process of fertilization, paternal
genome exchange protamines and DNA demethylation
and histone modifications occur (Santos et al. 2002). But
some area of heterochromatin in and around centromere
(Santos et al. 2002; Rougier et al. 1998), including
intracisternal A particle (IAP) retrotransposons (Lane et
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Clin Epigenet (2011) 2:27–53 37al. 2003) and permanently methylated imprinted genes
remain methylated (Olek and Walter 1997) for maintaining
the normal chromosome stability. The real mechanism and
cause of demethylation is unknown. It may be a part of the
process by which gametic genome return to embryonic
totipotency. The maternal genome remains epigenetically
unaffected. Before DNA demethylation, highly acetylated
histones are generally incorporated into the paternal
pronucleus (Santos et al. 2002; Adenot et al. 1997). Then
immediately, histones are deacetylated by HDACs and
monomethylated (Lepikhov and Walter 2004; Erhardt et al.
2003) with specific histone methyltransferase, including
SET 7/9 for H3K4me (Olek and Walter 1997), G9a and
ERG-associated protein with SET domain (ESET) for
H3K9me (Beaujean et al. 2004; Dodge et al. 2004), and
Ezh2 free unknown HMTase for H3K27me. These mo-
difications may be of help to protect the specific regions
from DNA demethylation. Recent data suggest that in
maternal pronucleus protection against DNA methylation is
related to H3K9me2 (Erhardt et al. 2003). Before blastocyte
stage when one cell develops to eight-cell stage, passive
demethylation takes place due to failure of maintenance
methylation that usually follows the DNA replication.
Oocytes containing DNMT1o leave the nucleus for first
three cleavage divisions (Carlson et al. 1992; Bestor 2000),
but at eight-cell stage it is only present in the nucleus
(Mertineit et al. 1998). After that in 16-celled embryo,
morula and blastocyte DNMT1o again appeared in cyto-
plasm. Cellular maintenance DNMT1 is expressed after
implantation (Howell et al. 2001). Remodeling of histone
during passive DNA demethylation is not clear. Firstly,
different epigenetic lineages appear in blastocyst as
embryonic and extraembryonic lineage, which are pluripo-
tent. Oct4 and Sox2 express in preimplantation stage which
maintains the pluripotenty of ES and Cdx2 express in
trophectoderm (TE). There are so many global differences
in DNA methylation and acetylation between two lineages.
H3K27me1, me2, and me3 more frequently found in ICM
than TE (Lepikhov and Walter 2004). DNA methyltrans-
ferases DNMT1, DNMT3a and DNMT3b, Ezh2, ESET,
and G9a (euchromatic H3K9 and perhaps H3K27 HMTase;
Dodge et al. 2004; Morgan et al. 2005) are important for
embryonic growth, not for TE lineage (Morgan et al. 2005).
After implantation, methylation levels increase in the
blastocyst inner cell mass, which is the progenitor of the
embryo proper. Parent-of-origin-specific-imprinting marks
must be removed in primordial germ cells (PGCs) and
thereafter established according to the sex of the individual.
Evidence indicates that this demethylation might also be
active [removal of the methyl group from methylated DNA
with the help of DNA repair based mechanisms or by a
direct DNA demethylase] (Patra et al. 2008; Patra and Szyf
2008). After fertilization at 7.5 days, PGCs arise from
epiblast in the posterior primitive and enter the genital ridge
between 8.5 and 11.5 days (Morgan et al. 2005). Until
day 13.5, they contentiously proliferate and then enter
either meiotic prophase I (females) or mitotic arrest until
birth (males, see Fig. 1). In between 11.5 and 13.5 days,
most methyl marks are erased in imprinted genes and single
copy genes (Gehring et al. 2009). PGCs at this stage
display an overall increase in nuclear size, loss, or down-
regulation of linker histone H1, H3K9me3, H3K27me3,
H4/H2AR3me2s, H2A.Z, and H3R26me2, and the disap-
pearance or redistribution of factors that are associated with
facultative or constitutive heterochromatin (Sasaki and
Matsui 2008; Hemberger et al. 2009). During this process,
presence of DNMT1 indicates that it is an active rather than
passive demethylation process, and implicates for the
presence of a DNA demethylase (Patra et al. 2008; Morgan
et al. 2005). Transposable elements, like IAP and long
interspersed nuclear element (LINE) resist demethylation to
a variable extent (Rakyan et al. 2003). Methylation patterns
are reestablished at later stages during gametogenesis by de
novo methyltransferases.
Pluripotent cells are characterized by distinctive cellular
markers and functions that relate to their uncommitted state.
Evidence from various sources has indicated that chromatin
might generally be less compact and more “transcription-
permissive” in undifferentiated ES cells compared with
differentiated cells. Differentiation of mouse and human ES
cell increases histone H4 deacetylation in pericentromeric
region and becomes heterochromatin in nature (Keohane et
al. 1996). Heterochromatinization pattern in ES cell and
differentiated cell is different. In case of lymphocyte cell,
many inactive genes are present near centromeric hetero-
chromatin (Brown et al. 1999). But in ES cell, this type of
gene inactivation was not observed (Smale 2003). Bi-valent
chromatin structure, in which active and repressive marker
are closely arranged, is a special epigenetic signature in
stem cell. This bi-valent chromatin structure decided which
of the highly conserved genes in ES cell, including
transcription factors of the Sox, Fox (forkhead box protein),
Pax (paired box gene), Irx, and Pou families become switch
on or off in later stages of embryonic development. A gene
with H3K27me3 is expressed when jointly associated with
di- or tri-methylated H3K4 in ES cell, but in differentiated
cell, including T-cell and neural progenitor cell genes with
only H3K27me3 was expressed when remained in promoter
region of many non-transcribed developmental genes
(Spivakov and Fisher 2007). In ES cell, a multiprotein
complex repressor protein, PcG plays a crucial role in
maintenance of pluripotency. At least four PcG have been
identified. Among them polycomb repressor complex (PRC)
1 and 2 are important for ES cells function maintenance.
PRC2 mainly consists of embryonic ectoderm development
(EED), suppressor of zeste 12 and the HMTase enhancer
38 Clin Epigenet (2011) 2:27–53EZH2, and catalyzes the methylation of H3K27. PRC1 can
bind with the methylated H3K27. Polycomb groups are
correlated with transcriptional repression of Nanog, Oct4,
and Sox2 which are the key controllers of Human ES cell
pluripotency. RING1A and RING1B which are main
proteins of PRC1 have ubiquitin ligase activity in case of
mono-ubiquitination of H2AK119 transcriptional regulator,
including Msx1 (muscle segment homeobox gene 1),
HoxA7, Gata4 are repressed by EED and RING1B which
are the key components of PRC2 and PRC1, respectively
(Spivakov and Fisher 2007). Other main important protein
groups are trithorax (trxG) group proteins, jumanji protein,
and SetDB1 proteins. Function of these proteins depends on
each other during ES cell development and differention.
TrxG proteins mainly proceed as transcriptional activator
protein. trxG has several groups including TAC1 (Trithorax
Acetylation Complex), SW1/SNF (SWItch/sucrose nonfer-
mentable), NURF, Ash1 (the absent, small or homeotic
discs1 gene), and MLL1–3 (mixed lineage leukemia1–3;
Ringrose and Paro 2004; Schuettengruber et al. 2007). TrxG
and PcG maintain transcriptional expression and repression
antagonistically by posttranslational modification of histone.
Two multiprotein complexes of trxG proteins have HMTase
activity. TAC1 group containing trithorax (Trx) protein
posseses both HATase and H3K4 HMTase activity (Petruk
et al. 2008). Another protein group, Ash1 methylates H3K4,
H3K9, H3K20, and H3K36. Human Trx homolog MLL1–3
group of trxG protein is responsible for H3K4 trimethylation
at human HOXA9 locus (Schuettengruber et al. 2007). The
PcG- and trxG-conserved group of proteins epigenetically
regulate several hundred important developmental genes
throughout the development, including abdA, AbdB in 2–6-
he m b r y o ,U b xi n2 –6-h embryo, larval brain, and larval
third leg disc, tumor-infiltrating lymphocyte gene in embryo
and larval brain, slam (signaling lymphocytic activation
molecule) in Drosophila embryo; HoxD cluster in human
Fig. 1 Embryo development and epigenetic reprogramming cycle.
Epigenetic modifications take place in two phases during the embryo
development. Fertilization signals the reprogramming during preim-
plantation development. I-A In preimplantation development just after
fertilization, DNA demethylation takes place in male pronucleus but
female pronucleus remains unchanged. I-B Thereafter, both genomes
are passively demethylated, except at imprinted genes and some
transposons, for several rounds of cell division. This demethylation
occurs due to disruption of maintenance methylation mechanism. I-C
The genome is de novo methylated around the blastocyst stage, which
responsible for differentiation of the first two lineages of the blastocyst
stage, the inner cell mass (ICM) and the trophectoderm. All embryonic
lineages differentiate from the ICM. II-A PGCs arise from somatic
tissue and develop into mature gametes during gametogenesis stage.
Their genome undergoes DNA demethylation in the embryo between
day 11.5 and 12.5, including all imprinted genes. II-B Following
demethylation, the genomes of the gametes are de novo methylated
and acquire imprints; this process continues up to 18.5 in males and in
maturing oocytes before ovulation in females
Clin Epigenet (2011) 2:27–53 39adult fibroblasts and Hox cluster in embryonic placenta and
adult tissue, etc. (Hekimoglu and Ringrose 2009). In
Drosophila or fly, they bind to the PcG and trxG response
elements; but in human, very little is known about these
regions (Hekimoglu and Ringrose 2009; Papp and Müller
2006). In ES cell, PcG protein complex and TrxG protein
maintain the “bivalent chromatin structure”. EZH2 catalyzes
H3K27Me3 and the ASH1 and Trx/MLL proteins catalyze
H3K4Me3 in ES cell which are determined the target gene
will become silent or active in differentiated cell (Hekimoglu
and Ringrose 2009). Misbalance in PcG/TrxG maintenance
may cause cancer or several rare genetic diseases. Mutation
in TrxG protein may cause leukemogenesis. After mutation,
a TrxG protein lin-59 that maintained the transcription of
Hox gene lin-39 is aberrantly activated. A LIN-39/CHE-20
(TALE-class Hox cofactor) complex binds to the promoter of
pro-apoptotic BH3-only gene egl-1 and inhibits the tran-
scription and allows survival of ventral cord (VC) neuron.
Downregulation of LIN-39 disrupted the regulatory mecha-
nism by allowing egl-1/BH3 transcription and may be the
cause of immature VC neuron death. LIN-39 overexpres-
sions due to mutation suppress the normal apoptosis and
promote leukemia (Potts et al. 2009). With PcG and TrxG
protein, jumanji group proteins are required for ES cells
differentiation and normal development. Large family of
jumanji-domain-containing proteins functions as histone
lysine demethylases, although functions of remaining few
members are unknown (Glass and Rosenfeld 2008)—
jumanjiC domain-containing histone demethylase (JHDMs)
such as JHDM 2A, 2C, 2B, and 2D are Fe(II) and α-
ketoglutarate-dependent protein that oxygenated methylated
histone lysine residue (Hamada et al. 2009). The UTX
(ubiquitously transcribed tetratricopeptide repeat X), UTY
(ubiquitously transcribed tetratricopeptide repeat Y) and
JMJD3 protein also are jumanjiC domain-contaning protein,
capable to demethylating H3K27Me3 at promoter region and
activate the gene expression. They are highly expressed in
ES cell and maintained demethylation of the Hox gene
promoter region and help Hox gene expression. They have a
significant role in X-chromosome inactivation and mainte-
nance (Karl et al. 2007; Sen et al. 2008). Jumanji and ARID
domain containing protein JARID2 forms a stable complex
with PRC2 that is responsible for recruit PcG protein to
heterologous promoter in ES cell. PCR2-JARID2 complex is
required for ES cell differentation (Pasini et al. 2010).
JHDMs has role in cancer development. It was shown that
JMJD2C is correlated with the abnormal growth of the
oesophagal squamous cancer and JMJD2A, 2B, and 2C are
involved in prostate cancer (Hamada et al. 2009). Apart from
these proteins, a H3K9 methyltransfarase named as SetDB1
has a very important role in maintaining ES cell develop-
ment and cell differentiation. Thirty-eight percent of
repressed gene in ES cell chromosome is co-occupied by
SetDB1 and PcG subunit Suz12 and repress the expression
of genes involve in cell differentiation. SetDB1 act as a
transcriptional repressor through H3K9Me3 (Bilodeau et al.
2009). Recent study suggests that at leatst two pathways
control the ES cell pluripotency and self renewal activity.
One is control by Nanog, Oct4, and Sox2 group which are
related with up or down-regulation of 474 genes. Another
group has estrogen-related receptor-β (Esrrb), T-box 3
(Tbx3), T-cell lymphoma breakpoint 1 (Tcl1) and develop-
mental pluripotency-associated 4 (Dppa4) genes which
couple with up or down regulation of 272 genes (Spivakov
and Fisher 2007, see Fig. 2)
Molecular marks for identifying cancer stem cells
Classical analyses of carcinogenesis implicated that every cell
within a tumor can develop a new primary tumor, and this
reasoning formed the basis for most tumor therapies to the
p r e s e n td a y( P a r d a le ta l .2003b). Current findings in the field
of tumor biology have suggested a stem-cell model of
carcinogenesis, which assumes that only a subset of tumor
cells are carcinogenic and are defined on their capability to
initiate tumor growth in serial transplantation models (Clarke
and Fuller 2006). These self-renewing cancer stem cells
(CSCs) or tumor-initiating cells (TICs) must not to be
confused with normal adult stem cells, which are pluoripotent
organ-specific cells that have the biological properties of self-
renewal and with each division they divided both progenitor
cells and at least one offspring that maintains the stem-cell
phenotype. There are a few similarities but the main
mechanism of SC and CSC formation are different. There
are three different models behind cancer propagation includ-
ing the CSC model, the clonal evolution model, and the
interconversion model. But it is not precisely restricted that a
cancer cell followed only one model. It may follow more than
one pathway which finally depends on genetic or epigenetic
changes in the cancer cell (Shackleton 2010a). Mainly two
theories behind the formation of CSC are related to epigenetic
changes. One theory is that CSCs arise from already
differentiated cell after some alteration and epigenetic changes
(Reya et al. 2001); another is transformation of immature
tissue stem cell or progenitor cell in tumor cell (Pardal et al.
2003a ;M i y o s h ie ta l .2009). Normal adult stem cells and
cancer cells occur from same origin/tissue and sometime
express same markers. Human mammary stem cells and some
breast cancers, both lack CD24 expression (Al-Hajj et al.
2003; Lim et al. 2009). Human acute myelogenous leukemia
stem cells and normal human hematopoietic stem cells both
are supplemented with the CD34+CD38− bone marrow
markers and also lack CD24 expression (Lapidot et al.
1994;S h a c k l e t o n2010b). Although normal and cancer stem
cells arise from same tissue and sometimes express same
markers, it is not mandatory that they always express same
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was induced by MLL-ENL (MLL-eleven nineteen leukemia),
MLL-AF9, and MOZ-TIF2 (monocytic leukemia zinc finger-
transcriptional mediators/intermediary factor 2) fusion gene
product had more similar phenotype to differentiated hemato-
poietic cells than hematopoietic stem cells, and tumorigenic
mammary cancer cells arising in mouse contain markedly
lower levelsof CD29expressionthannormal mousemammary
stemcells(Shackleton2010b). Severalstudiesshowthatmany
kind of developmental genes including Nanog, Ssea4 (Stage-
Specific Embryonic-Antigen-4), Tra-1–60 (Tumor Rejection
Antigen 1–60), and Tra-1–80 expression are misbalanced in
esophageal, stomach, colorectal, liver, pancreatic, and chol-
angiocellular cancer cells. These cancer cells are not able to
differentiate in different kind of cell line but when induced
pluoripotent stem (iPS) cells were prepared from this type of
cancer cell by inducing those genes that are able to
differentiate in ectoderm, mesoderm, and endoderm. These
iPS cells are capable to maintain almost all epigenetic status
including methylation of DNA strands and the H3K4 residue
in promoter regions of pluripotency-associated genes such as
NANOG (Miyoshi et al. 2009). More examples of such
epigenetic differences that are markedly observed in various
developmental and cancer cells are provided in Table 1 and
references 108–157 (cited in the Table).
Evidences are accumulating in favor of putative marker
candidates for cancers, including prostate TICs having
CD44, while the normal prostate stem cell lies within the
basal compartment (Tang et al. 2007). Various subpopula-
tions have been delineated as putative prostate TICs on the
basis of various cell-surface markers (Signoretti and Loda
2006). For instance, since most prostate tumors resemble
luminal cells (CK8+/18+AR+CD44−p63−), it had been
proposed that prostate TICs are due to the dedifferentiation
and transformation of luminal cells (Nagle et al. 1987; Liu
et al. 1999). Keratin profile and intrinsic androgen
independence, respectively, are other modes for analyz-
ing prostate cancer including the transit-amplifying cell
and basal cell. Characterization of prostate TICs have
been most promising with a basal cell subpopulation of
 = downragulation and  = expression. 
Fig. 2 During early embryogenesis, master transcriptional regulatory
genes and signaling pathways play essential roles in cell line
differentiation. Esrrb, Tbx3 and Tcl1, as well as Nanog, Oct4 and
Sox2, are required for self-renewal property of ES cells. Oct4 is
required to prevent trophectodermal differentiation; Nanog and Sox2
appear to be global regulators that repress multiple differentiation
programs, whereas Esrrb, Tbx3 and Tcl1 are essential to block the
differentiation into epiblast-derived lineages. These regulators couple
with transcriptional network and control the expression ofdifferent
genes through distinct molecular pathways. Downregulation of
Nanog, SOX2, ESRRB, Tbx3 or TCL1 leads to the immediate
induction of Otx2 (orthodenticle homolog 2), Pitx2 (paired-like
homeodomain transcription factor-2), Sox18 (SRY (Sex determining
region Y)-box 18), and probably additional genes, which help in the
differentiation of cell lineages in epiblast. Tead4 expresses when Oct4,
Nanog and Sox2 are repressed. Tead4 expression is responsible for
Cdx2 gene expression that is nesessary for placenta development.
Nanog directly repress GATA6, which results in repression of GATA4,
thereby inhibiting primitive endoderm differentiation
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vitro proliferative potential and can reconstitute prostatic-
like acini in immune-comprom i s e dm a l en u d em i c ew i t h
concomitant expression of differentiation markers, such
as AR, PAP, and K18. Prostate TICs typically represent
0.01% to 0.5% of the total cell population and they appear to
express many of the same markers as PSCs. Ultimately, the
characterization of TICs and the nature of their involvement in
prostatic carcinogenesis remain promising areas of investigation
(Joshua et al. 2008; van Leenders and Schalken 2001;
Verhagen et al. 1992; De Marzo et al. 1998; Bonkhoff and
Remberger 1996;R i c h a r d s o ne ta l .2004b). It has been
demonstrated that prostate TICs are, like PSCs, negative
for androgen receptor expression and predominantly
express the basal cell cytokeratins (Richardson et al.
2004b; Collins et al. 2005) and express higher mRNA
levels of several ESCs genes, including OCT3/4, BMI1,
β-catenin, and SMOOTHENED (Lawson et al. 2007;
Patrawala et al. 2006). Deleted in liver cancer 1 (DLC1), a
gene that encodes a Rho GTPase activating protein, is a
tumor suppressor gene in liver and other carcinomas.
Methylation of DLC1 gene increases in the prostate of
older man and expression of the DLC1 gene decreased.
This kind of gene repression may involve in early stage of
prostate cancer formation. From various studies, it is
revealed that hypermethylation is associated with early
stage cancer development and hypomethylation help in
progression of prostate cancer (Jaenisch and Bird 2003;
Feinberg et al. 2006; Jones and Baylin 2007; Patra et al.
2008; Schulz and Hoffmann 2009b).
Signaling cascades from membrane to nucleus
CSC's behaviors are constantly affected by external signals
from their niche, including neighboring stromal, immune,
and non-stem tumor cells. Extracellular and paracrine
effects are mediated commonly from cell-surface ligand-
receptor systems. Accumulating evidence has demonstrated
that cancer cells and CSC functions hinge on major
receptor-mediated pathways. For example, receptor tyrosine
kinases (RTK) family mediates the effects of multiple
oncogenic growth factor pathways, among which the EGFR
(epidermal growth factor receptor) is one of the best
characterized in cancers, including prostate cancer. Malig-
nant cancer cells frequently have increased EGFR signaling
as a result of either amplified EGFR copy number or
reciprocal crosstalk with TGF-β. The signal initiated by
RTKs is transduced and amplified through downstream
molecule cascades, such as Ras-MAPK, Ras-Raf-MEK-
ERK-Elk, and the pro-survival AKT/phosphoinositide 3-
hydroxykinase pathway [for an outstanding review, see
Patra 2008a, 2008b; for abbreviations, like EGFR etc. see
Supplementary Table 1].
Embryonic signaling, programming, and re-derived
pluripotency
Role for OCT4
The POU homeodomain containing, class 5, transcription
factor 1; POU5F1 (OMIM 164177), alternatively known
as octamer-binding transcription factor 3; OCT3/OTF3
and octamer-binding transcription factor 4; OCT4/OTF4
have been shown to be important regulators of tissue-
specific gene expression in early mammalian develop-
ment and in lymphoid and pituitary differentiation.
Takeda et al. (1992) amplified POU-related sequences in
human pancreatic islet mRNA by PCR and degenerating
oligonucleotide primers specific for the homeodomain
(Takeda et al. 1992). The sequences of both of the PCR
products were identical to human OCT1 (OMIM 164175),
and two others were homologous to mouse Oct3. They
showed that OCT3 gene spans about 7 kb and consists of
five exons, and two forms of OCT3 mRNA are expressed
in adult tissues as a result of alternative splicing—OCT3A
and OCT3B. OCT3A and OCT3B are composed of 360
and 265 amino acids, respectively, of which the 225 amino
acids at the COOH-termini are identical. The sequence of
human OCT3A showed 87% amino acid identity with
mouse Oct3. Reverse transcriptase PCR showed low level
of expression of both OCT3A and OCT3B mRNA in all
adult human tissues examined (Takeda et al. 1992). The
gene is specifically expressed in embryonic stem (ES)
cells but can also be detected in adult stem cells such as
bone marrow-derived mesenchymal stem cells. Expression
of Oct4 is downregulated during stem-cell differentiation.
Oct4 plays a critical role in maintaining pluripotency and
self-renewal of ES cells (Niwa et al. 2000), but its utility
as a marker of pluripotency has been challenged recently
by studies suggesting that it is expressed in a variety of
differentiated cells, including peripheral blood mononu-
clear cells. Requirements for Oct3/4 in the maintenance of
developmental potency in murine embryonic stem (ES)
cells were tested by conditional expression and repression
(Niwa et al. 2000). Although transcriptional determination
has usually been considered as a binary on–off control
system, Niwa et al. (2000) found that the precise level of
Oct3/4 governs three distinct fates of ES cells (Niwa et al.
2000). A less-than-twofold increase in expression causes
differentiation into primitive endoderm and mesoderm. In
contrast, repression of Oct3/4 induces loss of pluripo-
tency and dedifferentiation to trophectoderm. Thus, a
critical amount of Oct3/4 is required to sustain stem cell
self-renewal, and up- or downregulation induces diver-
gent developmental programs. Those findings established
a role for Oct3/4 as a master regulator of pluripotency that
controlslineage commitmentandillustratedthesophistication
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Oct4 expression by RT-PCR could be prone to artifacts
generated by pseudogene transcripts. We therefore suggest to
analyze the sequences of human Oct4 and its pseudogenes
and designed PCR primers that can avoid false-positive
detection of Oct4 expression. Oct3 plays many other roles,
including cardiac development in the early mouse embryo
(Zeineddine et al. 2006).
Mammalian forkhead box protein Foxd3 and Oct4
bound identical regulatory DNA sequences in the osteo-
pontin (SPP1; OMIM 166490) promoter (Guo et al. 2002).
It was observed that Oct4 interacted directly with Foxd3,
and osteopontin promoter was activated by both of the
proteins, either independently or in combination. However,
the activation of both Foxa1 (OMIM 602294) and Foxa2
(OMOM 600288) promoters by Foxd3 was inhibited by co-
expression of Oct4 (Guo et al. 2002). More significantly,
Oct4 neither bound to the forkhead box in the FoxA1 or
FoxA2 promoters that FoxD3 bound to, nor did it activate
transcription from these promoters. Significantly, Oct4
blocked the transcriptional activation of the FoxA1 and
FoxA2 promoters by FoxD3. This repression was specific
for FoxD3. Oct4 did not repress the activation of the FoxA1
or FoxA2 promoters by FoxA1 or FoxA2 proteins.
Immunoprecipitation studies found that Oct-4 could phys-
ically interact with the DNA binding domain of FoxD3,
which implies that when Oct-4 is not binding to DNA it can
function as a corepressor to inhibit the lineage-specific
promoters used here. It is possible that the dimerization and
conformational changes that Oct4 undergoes when it binds
DNA prevent it from acting as a corepressor of FoxD3.
When Oct-4 is not binding DNA, then it can bind to the
FoxD3 DNA-binding domain and repress FoxD3 transcrip-
tional activation. Two possible mechanisms for the inhibi-
tion of FoxD3 activation of FoxA1 or FoxA2 exist. First,
Oct4 could inhibit FoxD3 activation of the FoxA1 or
FoxA2 promoters by blocking binding of FoxD3 to the
Forkhead Box sequence in those promoters. Second, Oct-
4 could function as a true corepressor by decreasing
FoxD3 interaction with the transcriptosome apparatus. In
either case, this inhibition prevents inappropriate activa-
tion of endodermal promoters in a totipotent ES cell.
When Oct4 is downregulated after gastrulation and the
initial formation of the primitive endoderm, then FoxA1
and FoxA2 can be activated appropriately by the FoxD3,
which is still bound. Once activated, the proteins these
promoters generate will maintain expression throughout
organogenesis even as FoxD3 is downregulated (Guo et
al. 2002). Oct4 is one of the partners in the protein
network in which Nanog (OMIM 607937) operates in
mouse ES stem cells (Wang et al. 2006). The network is
highly enriched with nuclear factors that are individually
critical for maintenance of the ES cell state and co-
regulated on differentiation. The network is linked to
multiple co-repressor pathways and is composed of
numerous proteins whose encoding genes are putative
direct transcriptional targets of its members and this
network seems to operate as a cellular module dedicated
to pluripotency (Wang et al. 2006).
Mice with targeted disruption of the Oct4, or Oct3 gene
were generated by homologous recombination in ES cells
(Nichols et al. 1998). Oct4-deficient embryos developed to
the blastocyst stage with inner cell mass cells that were
restricted to differentiation along the extra-embryonic
trophoblast lineage, hence, were not pluripotent. Tropho-
blast proliferation was not maintained in Oct4 −/− embryos
in absence of a true inner cell mass. However, expansion of
trophoblast precursors was restored by an Oct4 target gene
product, fibroblast growth factor-4 (FGF4, OMIM 164980).
Therefore, Oct4 also determines paracrine growth factor
signaling from stem cells to the trophectoderm, and the
activity of Oct4 is essential for the identity of the
pluripotential founder cell population in the mammalian
embryo. In a very recent demonstration, Tay et al. (2008)
showed the existence of many naturally occurring miRNA
targets in the amino acid coding sequences of the mouse
Nanog, Oct4, and Sox2 genes and concluded that the
abundance of coding sequence-located miRNA targets,
some of which can be species-specific (Tay et al. 2008).
Retrovirus-mediated transfection of four transcription
factors, Oct3/4, Sox2 (OMIM 184429), c-Myc (OMIM
190080), and Klf4 (OMIM 602253) into mouse fibroblasts
generated induced pluripotent stem (iPS), from mouse
fibroblasts (Takahashi and Yamanaka 2006). Subsequently,
selection for Fbx15 (OMIM 609093) expression showed
that these iPS cells are similar to embryonic stem (ES) cells
in morphology, proliferation and teratoma formation.
However, iPS cells are different with regard to DNA
methylation patterns and gene expression, and fail to
produce adult chimeras. Interestingly, selection for Nanog
expression results in germline-competent iPS cells with
increased ES cell-like gene expression and DNA methyla-
tion patterns compared with Fbx15 iPS cells (Okita et al.
2007). The transgenes were strongly silenced in Nanog iPS
cells. The generation of mouse iPS cells by repeated
transfection of two expression plasmids, one containing
the cDNAs of Oct3/4, Sox2, and Klf4 and the other
containing the c-Myc cDNA, into mouse embryonic
fibroblasts resulted in iPS cells without evidence of plasmid
integration. These iPS cells produced teratomas when
transplanted into mice and contributed to adult chimeras.
The production of these virus-free iPS cells, albeit from
embryonic fibroblasts, addresses a critical safety concern
for potential use of iPS cells in regenerative medicine
(Morgan et al. 2005). The adult mouse neural stem cells
express higher endogenous level of Sox2 and c-Myc than
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with either Klf4 or c-Myc is sufficient to generate iPS cells
from neural stem cells (Kim et al. 2008).
Independently, by another group, it was demonstrated
that the transcription factors Oct4, Sox2, c-Myc, and
Klf4 can induce epigenetic reprogramming of a somatic
genome to an embryonic pluripotent state (Wernig et al. 2007).
Fibroblasts that had reactivated, in contrast to selection for
Fbx15 activation (Takahashi and Yamanaka 2006), the
endogenous Oct4 (Oct4-neo) or Nanog (Nanog-neo) loci
grew independently of feeder cells, expressed normal
Oct4, Nanog, and Sox2 RNA and protein levels, were
epigenetically identical to ES cells by a number of
criteria. Four factors, OCT4, SOX2, NANOG, and
LIN28 (OMIM 611043), were found sufficient to
reprogram human somatic cells to pluripotent stem cells
that exhibited the essential characteristics of embryonic
stem cells (Yu et al. 2007a). These induced pluripotent
human stem cells have normal karyotypes, express
telomerase activity, express cell-surface markers and genes
that characterize human ES cells, and maintain the
developmental potential to differentiate into advanced
derivatives of all three primary germ layers (Yu et al.
2007a). Using Oct4, Sox2, Klf4, and Myc iPS cells
derived from fetal, neonatal, and adult human primary
cells, including dermal fibroblasts isolated from a skin
biopsy of a healthy research subject (Park et al. 2008).
Human iPS cells resemble embryonic stem cells in
morphology and gene expression profile and in the
capacity to form teratomas in immune-deficient mice.
It was suggested that defined molecular components can
reprogram human cells to pluripotency. A method was
established to generate patient-specific cell lines in
culture (Park et al. 2008). Stadtfeld et al. (2008)
generated mouse iPS cells from fibroblasts and liver cells
by using nonintegrating adenoviruses transiently express-
ing Oct4, Sox2, Klf4, and c-Myc (Stadtfeld et al. 2008).
These adenoviral iPS cells showed DNA demethylation
characteristic of reprogrammed cells, expressed endogenous
pluripotency genes, formed teratomas, and contributed to
multiple tissues, including the germ cell line, in chimeric
mice.
Role for NANOG
Homeobox transcription factor NANOG (OMIM
607937). Embryonic stem (ES) cells derived from the
inner cell mass (ICM) of blastocysts grow infinitely
while maintaining pluripotency. Lif (OMIM, 159540)
can maintain self-renewal of mouse ES cells through
activation of Stat3 (OMIM 102582), but is dispensable
for maintenance of ICM and human ES cells. In search
of a critical factor(s) that underlies pluripotency in both
ICM and ES cells, Mitsui et al. (2003) performed an in
silico differential display and identified several genes
specifically expressed in mouse ES cells and preimplan-
tation embryos (Mitsui et al. 2003). One of them, encoding
a homeoprotein, the authors designated Nanog (from “Tir
Na Nog,” the mythologic Celtic land of the ever young)
was capable of maintaining ES cell self-renewal indepen-
dently of Lif/Stat3. The mouse Nanog cDNA contains an
open reading frame encoding a 305-amino acid polypep-
tide and has a long 3-prime untranslated region containing
a B2 repetitive element. The predicted Nanog protein
contains a homeobox domain that is most similar to those
of the Nk2 gene family (see 606727). The human Nanog
protein (FLJ12581) shares 52% overall amino acid identity
with the mouse protein and 85% identity in the homeo-
domain. Both human and mouse Nanog contain trp-rich
repeats, in which trp-x-x-x is repeated eight and ten times,
respectively. Human Nanog contains an Alu repetitive
element in the 3-prime untranslated region. EST database
searching identified clones corresponding to human Nanog
in libraries from NT2 human teratocarcinoma cells, germ
cell, and testis tumors, marrow, and other tumors. No EST
clones were detected in libraries from normal somatic
tissues. The NANOG gene contains four exons and spans
7k b( H a r te ta l .2004). The human NANOG protein
contains 305 amino acids (Chamber et al. 2003;C h a m b e r s
et al. 2007;C l a r ke ta l .2004). There are three splice
variants of mouse Nanog (Hart et al. 2004). The longest
variant encodes a 305-amino acid protein, and both shorter
variants encode a 279-amino acid protein. RT-PCR
detected Nanog expression in undifferentiated mouse
ES cells and embryonal carcinoma cells. In preimplan-
tation embryo, expression was detected in morula and
blastocysts, but little is known about how Nanog
expression is regulated. Nanog gene is transcribed under
the control of a regulatory region that lies within 332 bp
upstream of the transcriptional start site. Fox D3
(Forkhead Box Protein-D3) (Pan et al. 2006), Oct3,
and Sox2 are bind to the Nanog promoter region (Kuroda
et al. 2005) and positively regulate the transcription of
Nanog and TCF3 (Transcription factor 3, a transcription
factor that functions downstream of the Wnt pathway), and
p53 (Lin et al. 2005) negatively regulate the Nanog
transcription after binding to the promoter region. Leuke-
mia inhibitory factor and bone morphogenetic protein
(Matsuda et al. 1999) signaling and their downstream
effectors signal transducer and activator of transcription-3
(Matsuda et al. 1999; Suzuki et al. 2006)a n dT
(Brachyury, a novel family of putative transcription factor)
m a ya l s ob ei n v o l v e di nN a n o gr e g u l a t i o n( S u z u k ie ta l .
2006). Expression was present after implantation, but it
was downregulated after embryonic day 8.5. Low levels of
Nanog were detected in many adult mouse tissues. In situ
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mass in mouse blastocysts. Expression was downregulated
as epiblast cells entered the primitive streak and under-
went epithelial to mesenchymal transition. After the late-
bud stage, expression of Nanog waned, and it was not
detectable by day 8. In developing gonads, Nanog
expression was detected at embryonic day 11.5 (Hart et
al. 2004).
Role for MYC
The MYC (OMIM 190080, Gene map locus 8q24.12-
q24.13), a proto-oncogene encodes a DNA-binding factor
that can activate and repress transcription. Via this
mechanism, MYC regulates expression of numerous target
genes that control key cellular functions, including cell
growth and cell cycle progression. MYC also has a critical
role in DNA replication. Deregulated MYC expression
resulting from various types of genetic alterations leads to
constitutive MYC activity in a variety of cancers and
promotes oncogenesis (Dominguez-Sola et al. 2007). The
x-ray structures of the basic/helix-loop-helix/leucine zipper
(bHLHZ) domains of MYC-MAX and MAD (OMIM
600021)-MAX heterodimers bound to their common DNA
target, the enhancer box (E box) hexanucleotide (5-prime-
CACGTG-3-prime) was determined (Lee et al. 1997). E-
box recognition by these two structurally similar transcrip-
tion factor pairs determines whether a cell will divide and
proliferate (MYC-MAX) or differentiate and become
quiescent (MAD-MAX). Deregulation of MYC has been
implicated in the development of many human cancers,
including Burkitt lymphoma (OMOM 113970), neuroblas-
tomas, and small cell lung cancers. Induction of MYC
promotes cell proliferation and transformation by activating
growth-promoting genes, including the ornithine decarbox-
ylase (ODC1) and CDC25A gene (Nair and Burley 2003).
MYC transcriptionally represses the expression of the
growth arrest gene (GAS1; 139185). A conserved MYC
structure, MYC box 2, is required for repression of GAS1
and for MYC induction of proliferation and transformation,
but not for activation of ODC1 (Lee et al. 1997). Over-
expression of MYC in colorectal cancers is a commonly
observed phenomenon. MYC oncogene is a target in
adenomatous polyposis coli (APC; 611731)—beta-catenin
(CTNNB1; OMIM 116806) signaling pathway (He et al.
1998a). They showed that expression of MYC is repressed
by wild-type APC and activated by CTNNB1, and that
effects are mediated through T-cell factor 4 (TCF4; OMIM
602228) binding sites in the MYC promoter (He et al.
1998a). Inactivating mutations in the APC gene or DNA-
hypermethylation of promoter found in most colorectal
cancers, cause aberrant accumulation of CTNNB1 which
then binds TCF4 causing increased transcriptional activa-
tion of unknown genes. MYC directly activates telomerase
by inducing expression of its catalytic subunit; telomerase-
reverse transcriptase (TERT) (Wu et al. 1999). MYC
activity regulates a pathway linking cell proliferation and
chromosome integrity in normal and neoplastic cells.
However, TERT-driven cell proliferation is not genopro-
tective because it is associated with activation of the MYC
oncogene (Wu et al. 1999). Human mammary epithelial
cells, which normally stop dividing in culture at 55 to 60
population doublings (PDs), were infected with human
TERT retrovirus at PD40 and maintained until PD250
(Wang et al. 2000). MYC induces transcription of the E2F1,
2 and 3 genes in mouse embryonic fibroblasts. For S phase
arrest and indication of apoptosis by MYC a cell requires
distinct E2F activities. The ability of Myc to induce S phase
was impaired in the absence of either E2f2 or E2f3 but not
E2f1 or E2f4 (Wang et al. 2000).
MYC physically interacts with SMAD2 (Mothers
against decapentaplegic homolog 2) and SMAD3, two
specific signal transducers involved in TGF-beta signaling.
Through its direct interaction with SMADs, MYC binds to
the SP1-SMAD complex on the promoter of the p15
(INK4B) gene, thereby inhibiting the TGF-beta-induced
transcriptional activity of SP1 and SMAD/SP1-dependent
transcription of the p15 (INK4B) gene. The oncogenic
MYC promotes cell growth and cancer development partly
by inhibiting the growth inhibitory functions of SMADs
(Feng et al. 2002). Gao et al. (2009) reported that the c-Myc
oncogenic transcription factor also regulate microRNAs
and stimulate cell proliferation, transcriptionally represses
miR23a (OMIM 607962) and miR23b (OMIM 610723),
resulting in greater expression of their target protein,
mitochondrial glutaminase in human P-493 B lymphoma
cells and PC3 prostate cancer cells. (Gao et al. 2009)
Animal model studies implicated the role of MYC in
embryonic development, tissue regeneration, and cancer.
Baudino et al. (2002) have reported the lethality of c Myc-
null embryos by embryonic day 10.5 with defects in growth
and in cardiac, neural development, defects in vasculo-
genesis, and primitive erythropoiesis, and compromised
differentiation and growth of yolk sac and embryonic stem
(ES) cells. c-Myc expression was required for the expres-
sion of Vegf, angiopoietin-1, angiopoietin-2, and
thrombospondin-1, and expression of Vegf partially rescued
the lethal defects (Baudino et al. 2002). A reversible
transgenic mouse model of pancreatic beta-cell oncogene-
sis, using a switchable form of the MYC protein depicted
that activation of MYC in adult, mature beta cells induced
uniform beta-cell proliferation but was accompanied by
overwhelming apoptosis that rapidly eroded beta-cell mass
(Pelengaris et al. 2002). Brief MYC inactivation appears to
cause epigenetic changes in tumor cells that render them
insensitive to MYC-induced tumorigenesis. The authors
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may be an effective therapy for certain cancers (Jain et al.
2002). Langenau et al. (2003) described the induction of
clonally derived T cell acute lymphoblastic leukemia in
transgenic zebrafish expressing mouse c-Myc under the
control of the zebrafish Rag2 promoter. This transgenic
model provided a platform for drug screens and genetic
screens aimed at identifying mutations that suppress or
enhance c-MYC-induced carcinogenesis (Langenau et al.
2003). In transgenic mice that conditionally overexpressed
Myc in liver cells, upon Myc activation, all transgenic mice
developed liver tumors and succumbed to invasive liver
cancers. Myc inactivation induced tumor regression and the
differentiation of tumor cells into normal liver cells. Their
tumorigenic potential remained dormant as long as Myc
remained inactive; Myc reactivation immediately restored
their neoplastic properties (Shachaf et al. 2004). Ruggero et
al. (2004) have generated transgenic mice that overex-
pressed translation initiation factor-4E, a downstream
effector molecule of myc signaling axis, and observed a
marked increase in tumorigenesis in the mice compared
with their wild type littermates (Ruggero et al. 2004).
Sansom et al. (2007) have simultaneously deleted both Apc
and Myc in the adult murine small intestine and observed
that loss of Myc rescued the phenotypes of perturbed
differentiation, migration, proliferation, and apoptosis,
which occur on deletion of Apc. Remarkably, this rescue
occurred in the presence of high levels of nuclear beta-
catenin. Array analysis revealed that Myc is required for the
majority of Wnt (OMIM 164820) target gene activation
following Apc loss (Sansom et al. 2007). Cells transformed
with panel of oncogenes, other than MYC, escaped
apoptosis when treated with small-molecule CDK1
(cyclin-dependent kinases 1) inhibitors. The inhibitor of
apoptosis protein survivin (BIRC5; 603352), a non-CDK
target, was required for the survival of cells overexpressing
MYC in MYC-transformed cells. Inhibition of CDK1 had
rapidly downregulated survivin expression and induced
MYC-dependent apoptosis (Goga et al. 2007). Soucek et al.
(2008) used a dominant-interfering Myc mutant to deter-
mine both the therapeutic impact and side effects of Myc
inhibition in a preclinical mouse model of Ras (OMIM
190020)-induced lung adenocarcinoma. They showed that
Myc inhibition triggers rapid regression of incipient and
established lung tumors, defining an unexpected role for
endogenous Myc function in the maintenance of Ras-
dependent tumors in vivo. Systemic Myc inhibition also exerts
profound effects on normal regenerating tissues. However,
these effects are well tolerated over extended periods and
rapidly and completely reversible. These data demonstrated the
feasibilityoftargetingMyc,acommondownstreamconduitfor
many oncogenic signals, as an effective, efficient, and tumor-
specific cancer therapy (Soucek et al. 2008).
Role for hedgehog and wnt
The regulation of stem cells and in particular their
dysregulation in cancer is thought to occur through a
relatively small number of signaling pathways such as
Hedgehog and Wnt (Joshua et al. 2008). The name Wnt
was coined as a combination of Wg (wingless) and Int and
can be pronounced as “wint”. These pathways are all likely
to be co-regulated to maintain stem-cell homeostasis and
their dysregulation may be crucial to the emergence of a
TICs phenotype or morphological characteristics of more
advanced disease. The “Hedgehog” proteins are secreted
hydrophobic proteins that are made up of three signaling
genes Sonic hedgehog (Shh), Indian hedgehog, and Desert
hedgehog. Shh binds to the specific receptor, Patched, on
the cell surface. It ultimately activates an intracellular signal
transduction pathway activating the Gli (GLIoma-associated
oncogene homolog) family of transcription factors. This
family of transcription factors has multiple oncogenic effects:
(1)accelerationofproliferationratebyactivationofregulators
of G1/S and G2/M phase progression, (2) induction of Bcl-2
(B-cell lymphoma 2) and direct inhibition of apoptosis, and
(3) activation of epithelial to mesenchymal transition-
promoting factors such as Snail, and enhancement of
invasiveness and metastasis. Furthermore, there are multiple
control mechanisms at the membrane level with a second
transmembrane protein, Smo (Smoothened), a cell-surface
hedgehog ligand sequestration protein, Hip (also known as
Hedgehog interacting protein), transcription repression
through Gli3 and a cytoplasmic network of proteins including
Fused and SuFu (Suppressor of Fused). The expression of
these Hedgehog proteins is high in the fetal human prostate
and decreases to low levels in adult prostate tissue where it is
thought to regulate the prostatic epithelial homeostasis by
inhibiting proliferation and promoting terminal differentiation
ofducts (Joshua etal. 2008; Hooper and Scott 2005; Wang et
al. 2003; Karhadkar et al. 2004; Shaw and Bushman 2007).
Similar to the Hedgehog pathway, the Wnt pathway is
implicated in directing embryonic growth, and governing
processes such as cell fate specificity, proliferation, polarity,
and migration. The wingless gene had originally been
identified as a recessive mutation affecting wing and haltere
development in Drosophila melanogaster. It was subse-
quently characterized as segment polarity gene in D.
melanogaster that functions during embryogenesis and also
during adult limb formation during metamorphosis. The INT
genes were originally identified as vertebrate genes near
several integration sites of mouse mammary tumor virus.
The following is a list of human genes that encode WNT
signaling proteins: WNT1, WNT2, WNT2B, WNT3,
WNT3A, WNT4, WNT5A, WNT5B WNT6 WNT7A,
WNT7B WNT8A, WNT8B, WNT9A, WNT9B, WNT10A,
WNT10B, WNT11, and WNT16. The Int-1 gene and the
46 Clin Epigenet (2011) 2:27–53wingless genes were found to be homologous, with a
common evolutionary origin evidenced by similar amino
acid sequences of their encoded proteins. The canonical Wnt
pathway is characterized by binding of Wnt proteins,
through transmembrane receptors, to ultimately form a
complex with axin to induce its dephosphorylation. Axin
acts as a scaffold protein for a complex involving the APC
gene and beta-catenin, thereby facilitating phosphorylation
of both APC and beta-catenin by glycogen synthetase kinase
3B. As a consequence, cytoplasmic beta-catenin is trans-
located to the nucleus, where it associates with the T-cell
factor (Tcf) and lymphoid enhancer (LEF) family of tran-
scription factors. The beta-catenin/Tcf/LEF complex activates
transcription of target genes with relevance to carcinogenesis
including those that regulate cellular proliferation (c-MYC, c-
Jun, cyclinD1, cellular migration (uPA, CD44, MMP-7) and
cellular differentiation (FGF2, PPAR-gamma; Joshua et al.
2008; Ikeda et al. 1998; Kobayashi et al. 2000; Roose and
Clevers 1999;H ee ta l .1998b; Gounari et al. 2002;d el a
Taille et al. 2003).
Conclusion and perspectives
Recent research in cancer biology, including prostate cancer
has provided support for the cancer stem-cell hypothesis
(Blum et al. 2009). Two important components of this
hypothesis are that tumors originate in stem or progenitor
cells as a result of dysregulation of the normally tightly
regulated process of self-renewal. As a result, tumors contain
and are driven by a cellular subcomponent that retains key
stem-cell properties including self-renewal, which drives
tumorigenesis and differentiation that contributes to cellular
heterogeneity. Advances in stem-cell technology have led to
the identification of stem cells in normal and malignant
tissues. The study of these stem cells has helped to elucidate
the origin of the molecular complexity of human cancers.
The cancer stem-cell hypothesis has important implications
for early detection, prevention, and treatment of prostate and
other cancers. Notably, both hereditary and sporadic prostate
cancers may develop through dysregulation of stem-cell self-
renewal pathways. These aberrant stem cells may provide
targets for the development of cancer prevention strategies.
Furthermore, because prostate cancer stem cells may be
highly resistant to radiation and chemotherapy, the develop-
ment of more effective therapies for this disease may require
the effective targeting of this cell population.
The originofcancerstemcells isstill debated,but the most
probable hypothesis is that they arise from normal stem cells
over time, in a process that parallels, and in fact underlies, the
slow and multi-step development of cancer from normal
tissues (Miller et al. 2005). The rationale for this theory is
that stem cells, through their longer life span, are the only
cells able to accumulate all the mutations necessary to
initiate cancer. Furthermore, tissue-specific stem cells and
CSCs are notably similar, sharing fundamental abilities of
self-renewal and differentiation (Martínez-Climent et al.
2006). DNA methylation and PRCs were analyzed by a
new experimental and analytical strategy using customized
high-density tiling arrays to investigate coordinated patterns
of gene expression (Gal-Yam et al. 2008). Both DNA
methylation and polycomb marks differentiate cancer cells
from their normal counterparts. Disruption of bivalent
chromatin profile in ES cell may also be responsible for
cancer formation. Control of gene expression by key
regulatory genes (Nanog, Oct4, Sox2, Esrrb, Tbx3, Tcl1,
and Dppa4), passive or active DNA methylation/demethyla-
tion and histone modification maintain pluripotency and self-
renewal character in ES cell. They also help in embryo
development and cell differention. Three major changes in
the epigenomic landscape distinguished the two cell types.
Developmentally, significant genes containing CpG islands
which are silenced by PRCs in the normal cells acquire
DNA methylation silencing and lose their PRC marks
(epigenetic switching). Because these genes are normally
silent this switch does not cause de novo repression but
might significantly reduce epigenetic plasticity. Two other
groups of genes are silenced by either de novo DNA
methylation without PRC occupancy (5mC reprogramming)
or by de novo PRC occupancy without DNA methylation
(PRC reprogramming). These data suggested that the two
silencing mechanisms act in parallel to reprogram the cancer
epigenome and that DNA hypermethylation may replace
polycomb-based repression near key regulatory genes,
possibly reducing their regulatory plasticity. Any small
mistake in these vital control systems may cause cancer.
Unlike genetic alterations, epigenetic changes are potentially
reversible. The large-scale development of small-molecule
inhibitors of DNA and histone-modifying enzymes is now in
full swing. Clear information about epigenetic altaration
makes a glorious path in cancer biology research. In the
clinic, the success of HDAC inhibitors and DNA demethylat-
ing agents like aza cytidine as anti-cancer drugs demonstrates
“proof of principle” of this approach and provides great hope
for the development of a more comprehensive portfolio of
“epigenetic drugs” in the future.
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